XML 53 R40.htm IDEA: XBRL DOCUMENT v3.5.0.2
4. LICENSING AGREEMENTS (Details Narrative) - USD ($)
12 Months Ended
Apr. 30, 2016
Apr. 30, 2015
Apr. 30, 2014
Research and development expense $ 59,529,000 $ 42,996,000 $ 27,723,000
License revenue 329,000 37,000 107,000
Bavituximab Program [Member] | Milestone Obligations Expense [Member]      
Research and development expense   0 125,000
Bavituximab Program [Member] | Milestone Obligations Expense [Member]      
Research and development expense 0    
UTSWMC License [Member] | Milestone Obligations Expense [Member]      
Research and development expense 75,000 0 0
Affitech Agreements [Member]      
License revenue $ 37,000 $ 37,000 $ 107,000